Eswatini Embraces Nuclear Tech for Progressby Lilu Anderson 18.08.2024Eswatini leverages nuclear tech for sustainable growth in agriculture, healthcare, and energy with IAEA support.
Top Biotech ETFs for Diversificationby Lilu Anderson 15.08.2024Explore top biotech ETFs like XBI, BBH, and IBB, offering potential returns and portfolio diversification in a growing market.
Beam Therapeutics: Genetic Medicine Pioneerby Lilu Anderson 15.08.2024Beam Therapeutics leads with CRISPR in treating genetic diseases, opening new market avenues.
Addressing AI Bias in Medical Settingsby Lilu Anderson 14.08.2024Exploring the impact of AI bias in healthcare and solutions to ensure equitable patient care.
Kezar Shifts Focus From Tumor Drug to Autoimmune Therapyby Lilu Anderson 14.08.2024Kezar halts tumor drug trials, pivots to autoimmune hepatitis focus with promising zetomipzomib.
Lilly Boosts R&D with $700M Boston Centerby Lilu Anderson 13.08.2024Lilly's new Boston facility enhances RNA/DNA research, hosting 500 scientists and expanding Gateway Labs to the East Coast.
Recursion Merges with Exscientia to Accelerate Drug Discoveryby Lilu Anderson 13.08.2024Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
Amgen to Launch Tech and Innovation Hub in Indiaby Lilu Anderson 12.08.2024Amgen plans a new site in Hyderabad to boost digital capabilities and advance its medicine pipeline.
Amgen to Launch Innovation Hub in Hyderabadby Lilu Anderson 12.08.2024Amgen taps into India's talent with new Hyderabad innovation site for advancing biotechnology and AI.
23andMe Reports Q1 Revenue Drop, Narrows Lossesby Mark Eisenberg 10.08.202423andMe's Q1 revenue declines by 34% but narrows losses. Focus on AI and genetic studies drives future growth.